Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 8:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,153 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Part 1 Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Effects of GLP-1 RAs on Human Lactation Outcomes

NCT07720414
View directory record Official record
Conditions
Lactation, Weight Loss
Interventions
Injected GLP-1 Receptor Agonists and Dual Agonists
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 25, 2026, 8:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function

NCT02729038
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 25, 2026, 8:35 AM EDT
Completed Phase 2 Interventional

Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function

NCT01794663
View directory record Official record
Conditions
Delayed Graft Function
Interventions
OPN-305, Placebo
Drug
Lead sponsor
Opsona Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Sep 25, 2026, 8:35 AM EDT
Active, not recruiting Not applicable Interventional

Project BIPAMS: Behavioral Intervention for Physical Activity in Multiple Sclerosis

NCT03490240
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIPAMS, WELLMS
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 64 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 25, 2026, 8:35 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

NCT06567314
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
Ivonescimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 25, 2026, 8:35 AM EDT
Completed Phase 1 Interventional

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

NCT01629758
View directory record Official record
Conditions
Neoplasms by Site
Interventions
Denenicokin, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 25, 2026, 8:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.

NCT00838058
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy Volunteers
Interventions
CE 224,535
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2009 · Synced Sep 25, 2026, 8:35 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Massage: Neuroimaging and Correlates of Response - 6-week Study

NCT07190326
View directory record Official record
Conditions
Healthy Control
Interventions
Swedish Massage Therapy, Light Touch Control
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 25, 2026, 8:35 AM EDT
Recruiting Phase 1 Interventional

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

NCT07399678
View directory record Official record
Conditions
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Interventions
ALV-100, Placebo
Drug
Lead sponsor
Alveus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Miami, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 25, 2026, 8:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole SAD/MAD Study

NCT01449578
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Dexpramipexole Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 25, 2026, 8:35 AM EDT
Completed Phase 1 Interventional Results available

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

NCT04478708
View directory record Official record
Conditions
Obesity
Interventions
maridebart cafraglutide, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Anaheim, California • Tustin, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 25, 2026, 8:35 AM EDT
Completed Phase 1 Interventional Results available

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

NCT02723955
View directory record Official record
Conditions
Neoplasms
Interventions
feladilimab (GSK3359609), GSK3174998, Pembrolizumab, Docetaxel, Pemetrexed, Paclitaxel plus Carboplatin, Gemcitabine plus Carboplatin, Fluorouracil (5-FU) plus carboplatin or cisplatin, Dostarlimab, Cobolimab, Bintrafusp alfa
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 93 Years
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 25, 2026, 8:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

NCT01906385
View directory record Official record
Conditions
Glioma
Interventions
Rhenium Liposome Treatment
Drug
Lead sponsor
Cerenome
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Manhasset, New York • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 25, 2026, 8:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Early Characteristics of Autism

NCT00090415
View directory record Official record
Conditions
Autism, Autistic Disorder
Interventions
Intensive behavioral therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Months to 30 Months
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Sep 25, 2026, 8:35 AM EDT
Completed Not applicable Interventional

Insulet Artificial Pancreas Evaluating Meal Performance and Moderate Exercise (IDE2)

NCT03064906
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulet AP (artificial pancreas) System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
3
States / cities
Palo Alto, California • Walnut Creek, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Sep 25, 2026, 8:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Healthy Eating and Active Living Taught at Home (HEALTH) Dissemination & Implementation (D&I)

NCT03758638
View directory record Official record
Conditions
Obesity
Interventions
Healthy Eating & Active Living Taught at Home, Usual Care
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 25, 2026, 8:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

NCT06567015
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
STX-241
Drug
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 25, 2026, 8:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

NCT04742634
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
DEC-C, MyeloSeq-HD
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 25, 2026, 8:35 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

NCT03355209
View directory record Official record
Conditions
Lennox Gastaut Syndrome
Interventions
ZX008 0.2 or 0.8 mg/kg/day, Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 35 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
30
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 25, 2026, 8:35 AM EDT
Active, not recruiting No phase listed Observational

A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis

NCT03127709
View directory record Official record
Conditions
Histiocytosis
Interventions
Trail Making Test, Parts A & B, Brief Test of Attention, Symbol Span, Controlled Oral Word Association Test, The Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Hospital Anxiety and Depression Scale, McGill Quality of Life Scale, MR Brain Imaging, Resting state functional MRI, Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)
Behavioral · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 25, 2026, 8:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

NCT03081858
View directory record Official record
Conditions
Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urinary Bladder, Transitional Cell Carcinoma of the Bladder, Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Urinary Bladder Diseases, Urologic Diseases
Interventions
TSD-001
Drug
Lead sponsor
Lipac Oncology LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 25, 2026, 8:35 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT06710132
View directory record Official record
Conditions
Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
M9140
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Santa Monica, California • Santa Rosa, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 25, 2026, 8:35 AM EDT
Terminated Phase 1 Interventional

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

NCT04249947
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site, Prostatic Disease, Salivary Gland Cancer, Salivary Gland Tumor, Adenoid Cystic Carcinoma, Salivary Duct Carcinoma, Mucoepidermoid Carcinoma, Acinic Cell Tumor
Interventions
P-PSMA-101 CAR-T cells, Rimiducid
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Duarte, California • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 25, 2026, 8:35 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

NCT04208178
View directory record Official record
Conditions
Advanced HER2+Breast Cancer
Interventions
Alpelisib, Alpelisib matching Placebo, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Fayetteville, Arkansas • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 25, 2026, 8:35 AM EDT